New FDA-Approved Label of ED Drugs Contains Risk of Hearing Loss

Filed in archive FDA Approvals , Men's Health , News on October 23, 2007

Revisions of the labeling of ED drugs (Cialis, Levitra and Viagra) that includes the potential risk of sudden hearing loss have already been approved by the FDA.




The said approval will also apply for the drug Revatio (also a member of this drug class known as phosphodiesterase type 5 (PDE5) inhibitors) even though Revatio is used to treat pulmonary arterial hypertension (PAH) - a serious medical condition in which continuous high blood pressure in arteries of the lungs weakens the heart muscle (often leading to right heart failure and death).

Erectile dysfunction (ED) drugs will noe display more prominently the potential risk of sudden hearing loss, and to guide consumers on what to do if they experience sudden problems with their hearing.

Patients taking Cialis, levitra, or Viagra who experience sudden hearing loss should immediately stop taking the drug and seek prompt medical attention. Those using Revatio should continue taking their medication but should contact their health care provider for further evaluation.

Because Revatio is used to treat a potentially life-threatening condition, the FDA does not recommend patients abruptly stop taking this medication but should consult their physician if they experience sudden problems with their hearing.

Again, men should be careful about intake of ED drugs which may be a wonder drug to some, but doesn't come with no side effects.

Find more details from the FDA News.